US: Pharmaceuticals
More
-
REDWOOD CITY, Calif.-- Shares of AcelRx Pharmaceuticals Inc. hit an all-time high price Tuesday, after the specialty drugmaker said its NanoTab pain treatment system met its main goal in late-stage research, and the company is preparing to submit it to regulators for approval.
-
The revenue hit faced by Cubist Pharmaceuticals from generic competition may not be as dramatic as it has been for other drugs, Cantor Fitzgerald said Tuesday, as it raised its rating on the drugmaker.
-
May 21- A new type of asthma drug meant to attack the underlying causes of the respiratory disease slashed episodes by 87 percent in a mid-stage trial, making it a potential game changer for patients with moderate to severe disease, researchers said on Tuesday.
-
Drugmaker Pfizer Inc. has halted a late-stage study of an experimental cancer compound being tested in patients with a certain form of non-Hodgkin's lymphoma, because an interim analysis showed the drug wasn't helping patients live longer.
-
The ASCO meeting scheduled to begin on May 31st could generate a cornucopia of health care catalysts, said Jim Cramer.
-
May 20- Merck& Co's experimental insomnia drug suvorexant appears generally effective, according to reviewers at the U.S. Food and Drug Administration, but they questioned the company's proposed dosing levels.
-
May 20- Generic drugmaker Actavis Inc, which has been the subject of intense takeover speculation, said on Monday that it had struck a deal to buy specialty pharmaceuticals company Warner Chilcott Plc for $8.5 billion in stock.
-
*Pilot scheme in Jakarta triggered overcrowding at hospitals. JAKARTA, May 20- When a sick Indonesian baby died after 10 hospitals in Jakarta turned her family away in February, critics blamed a pilot health insurance scheme that had overwhelmed the city's public hospitals.
-
Cramer has been looking at long-term losers to see if any show potential. He’s found something.
-
*Novartis' one-third stake in Roche built up under Vasella. ZURICH, May 16- A changing of the guard at Switzerland's two biggest drugmakers is fuelling talk that Novartis may finally sell its multi-billion-dollar stake in cross-town rival Roche, potentially unlocking value for both sets of shareholders.
-
The Parsippany, N.J., company's stock had already climbed about 16 percent since last Friday, when Actavis and Irish drugmaker Warner Chilcott PLC said that they were in early talks about a possible combination but had reached no agreement yet. Actavis shares rose 62 cents to $124.50 in premarket trading about 40 minutes ahead of Thursday's market opening.
-
NEW YORK, May 15- Before Optimer Pharmaceuticals Inc even put itself up for sale earlier this year, Cubist Pharmaceuticals Inc offered to buy the antibiotic maker for $20 per share, or nearly $1 billion, two people familiar with the matter told Reuters on Wednesday.
-
CHICAGO/ NEW YORK, May 15- Shares of drugmaker Bristol-Myers Squibb Co rose to a 10- year high on Wednesday ahead of results of an early stage trial for its new melanoma treatment, with heavy betting in the options market suggesting investors see more gains in the stock.
-
NEW YORK, May 15- Swiss drugmaker Roche Holding AG is exploring a sale of its blood glucose meters business, three people familiar with the matter told Reuters on Wednesday, as the industry grapples with increased competition and reimbursement pressure.
-
CHICAGO/ NEW YORK, May 15- Shares of drugmaker Bristol-Myers Squibb Co rose to a ten-year high on Wednesday ahead of results of an early stage trial for its new melanoma treatment, with heavy betting in the options market suggesting investors see more gains in the stock.
-
A 65-year-old couple retiring this year would need $220,000 on average to cover medical expenses, an 8 percent decrease from last year's estimate. But most people estimate just a fraction of that.
-
PIERRE, S.D.-- Attorney General Marty Jackley says South Dakota will get more than $1 million as its share of a national settlement with a pharmaceutical manufacturer that allegedly distributed substandard drugs.
-
NEW YORK-- Weight loss drug maker Vivus Inc. said Tuesday it plans to sell $200 million in convertible senior debt due in 2020 in a private transaction. Vivus said the initial purchasers will have the option to buy another $30 million in notes, which are due May 1, 2020. Shares of Vivus lost 40 cents, or 3 percent, to $13.19 in morning trading.
-
Actavis received and rejected a takeover offer from Mylan last week that valued the generic drugmaker at more than $15 billion, a person familiar with the situation said.